STRO

Insider Trades

Name	Value	Action	Price	Current Price
Matsui ConnieDirector $40k50k shares BuyOct 15, 2025 $0.799 --
Chow Gregory K.CFO $16k19.8k shares BuyOct 15, 2025 $0.81 --
Chung JaneDirector, Officer: Chief Executive Officer $10k12.5k shares BuyOct 15, 2025 $0.8009 --
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER $14k17k shares BuyOct 15, 2025 $0.8004 --
Pauling DavidChief Admin. Ofcr. & GC $10.0k12.5k shares BuyOct 15, 2025 $0.7992 --

News

globenewswire.comSutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlightsglobenewswire.comMay 14

247wallst.comHere Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More247wallst.comApr 30

globenewswire.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026globenewswire.comApr 19

defenseworld.netSutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgradedefenseworld.netApr 18

zacks.comSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?zacks.comApr 8

Trade STRO

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

CEO: Jane Chung
IPO Date: Sep 27, 2018

Market Data

Open: $28.70
High: $29.90
Low: $27.69
Volume: 230.5K
Avg Volume: 278.4K
52W High: $43.85
52W Low: $6.70

Valuation

Market Cap: $287M
Enterprise Value: $227M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-179M
Revenue: $102M
Net Income: $-191M
Cash: $58M
Debt: $16M

Events

EarningsAug 6

EPS est. -2.19736